JP5527549B2 - C型肝炎治療剤 - Google Patents
C型肝炎治療剤 Download PDFInfo
- Publication number
- JP5527549B2 JP5527549B2 JP2010533943A JP2010533943A JP5527549B2 JP 5527549 B2 JP5527549 B2 JP 5527549B2 JP 2010533943 A JP2010533943 A JP 2010533943A JP 2010533943 A JP2010533943 A JP 2010533943A JP 5527549 B2 JP5527549 B2 JP 5527549B2
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- hcv
- therapeutic agent
- cells
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000005176 Hepatitis C Diseases 0.000 title claims description 47
- 239000003814 drug Substances 0.000 title claims description 26
- 229940124597 therapeutic agent Drugs 0.000 title claims description 25
- 102000006992 Interferon-alpha Human genes 0.000 claims description 22
- 108010047761 Interferon-alpha Proteins 0.000 claims description 22
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 17
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 description 29
- 230000000694 effects Effects 0.000 description 23
- 108060001084 Luciferase Proteins 0.000 description 14
- 230000010076 replication Effects 0.000 description 13
- 239000005089 Luciferase Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000012216 screening Methods 0.000 description 8
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 7
- 208000010710 hepatitis C virus infection Diseases 0.000 description 7
- 208000006154 Chronic hepatitis C Diseases 0.000 description 6
- 241000710188 Encephalomyocarditis virus Species 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 241000242739 Renilla Species 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940096120 hydrea Drugs 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- -1 elixirs Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
経口投与用のカプセルの組成の1例として次のものを例示することができる。
HU 500mg
ハイドレアカプセル(ブリストルマイヤーズ) 500mg
本願発明者らが開発した、特許文献1記載の細胞を用いたスクリーニング系により、C型肝炎治療効果を有する化合物をスクリーニングした。
(1) 細胞培養と抗ウイルスアッセイ
OR6細胞は、24ウェル中で培養した(培養液:5%牛胎児血清及びG418付加DMEM培地、温度37℃)。HUとインターフェロンα(以下、「IFNα」)の抗ウイルス効果をモニターするため、まず24ウェルプレートを用いて1ウェルあたり15000細胞を24時間培養した。引き続いて種々の濃度のHUやIFNαあるいは両剤を加えさらに72時間培養した。各ウェル中の細胞を回収し、ルシフェラーゼ活性を測定した。ルシフェラーゼ活性は、市販のルシフェラーゼ活性測定キット(Renilla Luciferase Assay System (Promega社))を用い、添付の実験説明書に従って細胞を回収し、ルシフェラーゼの定量を行うことにより測定した。蛍光活性の測定にはMonolight 3010(BD Biosciences社)を用いた。
純度98%以上のHU及びIFNαはシグマアルドリッチ社より購入した。
OR6細胞に対するHUの細胞毒性を検証するため、95mm培養皿にOR6細胞を400000個まき、0、50、100、150μmol/Lの濃度でHUを加え72時間培養した。トリパンブルー染色の後で生存している細胞数をヘマトサイトメーターにて測定した。
特許文献1に従い脳心筋炎ウイルス(EMCV)由来内部リボソーム侵入部位(IRES)によりレニラ蛍光をコードするプラスミドをIFNにより治癒したOR6細胞であるOR6c細胞にFuGENE6試薬(Roche Diagnostics社製)を用いてトランスフェクションし、24時間後に種々の濃度のHUを加え72時間培養した。
(1) HUは単独でHCV遺伝子複製抑制効果を示した
OR6細胞はHCV遺伝子複製をモニターする信頼できる実験系と考えられているため、HUが単独でHCV全長遺伝子の複製を抑制できるか検討した(図1A)。150μmol/LまでのHUを72時間投与して得られた用量依存曲線により、50%複製抑制濃度(無添加の場合の複製を50%抑制する濃度)は60μmol/Lとなった(図1B)。インターフェロンαの50%抑制濃度は1.2 IU/mlとなった。コントロールプラスミドpEMCV-RLをトランスフェクションした治癒OR6c細胞を用いて、HUはレニラ蛍光自身を発光抑制しないことを確認した(図2)。これらの結果より、HUは独立してHCV遺伝子複製を抑制できることが明らかになった。
HCVレプリコンの複製は宿主細胞の増殖に依存するという報告があるため、HUのHCV遺伝子複製抑制効果が細胞毒性効果のため生じている可能性がある。この可能性を除外するため、OR6細胞に対するHUの細胞毒性効果を検証した。その結果、100μmol/LまでのHUで処理した細胞では未処理の細胞と比較して生存細胞数に明らかな差は認められなかった(図3)。
続いてHCV全長遺伝子複製におけるインターフェロンαとHUの併用による抑制効果を検討した。HUを0、24、48マイクロモルに固定した時のインターフェロンαの用量依存曲線が得られた。曲線はHUを加えることにより左にシフトしており(図4A)、HU併用はインターフェロン単独より効果的であることが示された。アイソボログラム解析により両剤併用による相乗的な抗HCV効果が証明された(図4B。図4B中の破線が相乗効果がない場合(相加効果)のラインであり、実測値がそれよりも左下側にあることは、IFNα単独投与よりもHUとの併用の方が抗HCV効果が高まること、すなわち、相乗効果があることを示す)。これらの結果よりHUはインターフェロンαと併用して使用できる抗HCV剤となり得ることが明らかになった。
インフォームドコンセントを施した12名の難治性C型肝炎患者(serogroup 1 高ウイルス量)に対してハイドロキシウレア(商品名ハイドレアカプセル)1500mg/日の経口投与を4週間行った。投与開始前から治療終了時まで1週間毎に血清中HCV RNA量(log IU/ml)を常法である、TaqMan(商品名)プローブを用いたリアルタイム検出PCR法により測定した。
Claims (3)
- ハイドロキシウレアを有効成分として含有するC型肝炎治療剤。
- インターフェロンαをさらに含む請求項1記載の治療剤。
- ハイドロキシウレアのC型肝炎治療剤製造のための使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010533943A JP5527549B2 (ja) | 2008-10-17 | 2009-10-16 | C型肝炎治療剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008268679 | 2008-10-17 | ||
JP2008268679 | 2008-10-17 | ||
JP2010533943A JP5527549B2 (ja) | 2008-10-17 | 2009-10-16 | C型肝炎治療剤 |
PCT/JP2009/067942 WO2010044474A1 (ja) | 2008-10-17 | 2009-10-16 | C型肝炎治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2010044474A1 JPWO2010044474A1 (ja) | 2012-03-15 |
JP5527549B2 true JP5527549B2 (ja) | 2014-06-18 |
Family
ID=42106638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010533943A Expired - Fee Related JP5527549B2 (ja) | 2008-10-17 | 2009-10-16 | C型肝炎治療剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20110200554A1 (ja) |
JP (1) | JP5527549B2 (ja) |
WO (1) | WO2010044474A1 (ja) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3968249A (en) * | 1963-01-22 | 1976-07-06 | E. R. Squibb & Sons, Inc. | Method of treating malignant neoplastic disease |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
-
2009
- 2009-10-16 WO PCT/JP2009/067942 patent/WO2010044474A1/ja active Application Filing
- 2009-10-16 US US13/124,584 patent/US20110200554A1/en not_active Abandoned
- 2009-10-16 JP JP2010533943A patent/JP5527549B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2010044474A1 (ja) | 2010-04-22 |
US20110200554A1 (en) | 2011-08-18 |
JPWO2010044474A1 (ja) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5185826B2 (ja) | ウイルス性肝炎の処置 | |
JP5539363B2 (ja) | インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ | |
AU2019271958B2 (en) | Therapy for inhibition of single-stranded rna virus replication | |
JP2020196750A (ja) | 線維症を処置するためのセニクリビロック併用療法 | |
JP2009522371A5 (ja) | ||
US20180110796A1 (en) | Compositions and methods for the treatment of hbv infection | |
US20130109647A1 (en) | Methods and compositions for treating hepatitis c virus | |
EP2776024A1 (en) | Methods and compositions for treating hepatitis c virus | |
KR20120048706A (ko) | 뇌종양 치료 방법 | |
TWI631943B (zh) | 治療脂肪肝疾病之方法 | |
US20100086519A1 (en) | Treatment of Hepatitis C Infection With Metalloporphyrins | |
JP5527549B2 (ja) | C型肝炎治療剤 | |
JP5114401B2 (ja) | ウイルス性疾患の予防又は治療剤 | |
US11364256B2 (en) | Viral inhibition | |
WO2021180251A1 (zh) | 治疗冠状病毒感染的联用药物及治疗方法 | |
JP5061352B2 (ja) | 肝臓疾患治療剤及び肝機能改善剤 | |
WO2022213870A1 (zh) | 通过口服给药抑制CD4+Treg细胞的药物和方法 | |
CN104780918B (zh) | 用于预防和/或治疗丙型肝炎的氮杂环丁酮化合物及其组合物 | |
WO2016139740A1 (ja) | 肝線維化改善剤 | |
US20230014055A1 (en) | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | |
WO2017202789A1 (en) | Methods and pharmaceutical compositions for the treatment of filovirus infections | |
JP2005527552A (ja) | 置換アクリロイルジスタマイシン誘導体および放射線療法を含む腫瘍に対する組合せ治療 | |
WO2016164625A1 (en) | Compositions and methods for the treatment of hcv infection | |
JP2017514834A (ja) | Hcv感染症を治療するための組合せ療法 | |
CN101180053A (zh) | 铁在发病机制中发挥作用的肝病的治疗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120903 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140401 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5527549 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |